No evidence yet that itolizumab, tocilizumab reduces deaths: ICMR

Director-General of the ICMR Balram Bhargava has said there is yet no evidence from trials that itolizumab and tocilizumab, two drugs, one of which has been developed by Bengaluru-based Biocon Biologics, reduce death in severely ill coronavirus (COVID-19) patients. Continue Reading